Soft tissue sarcoma · 4 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Pembrolizumab and RT Variant #02 | — | R 327 949 | 63d | — | — | — | — | — |
Epirubicin and Ifosfamide Variant #03 | — | R 27 105 | 21d | — | — | — | — | — |
EIA Variant #01 | — | R 12 711 | 21d | — | — | — | — | — |
No neoadjuvant therapy Partial | — | — | — | ~26.4 mo | ~37.0 mo | — | — | 12 |
4 of 4 regimens shown